HomeGeneticsGeneCUL7 gene
Back to Gene
CUL7 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CUL7 gene

The CUL7 gene provides instructions for making the protein cullin-7, which is a critical component of the cell's quality control system for protein degradation.

Normal Function

The CUL7 gene provides instructions for making a protein called cullin-7. This protein plays a role in the ubiquitin-proteasome system, which is the cell machinery that breaks down (degrades) unwanted proteins.

Cullin-7 helps assemble a complex known as an E3 ubiquitin ligase. This complex tags damaged and excess proteins with molecules called ubiquitin. Ubiquitin serves as a signal to specialized cell structures known as proteasomes, which attach (bind) to the tagged proteins and degrade them. The ubiquitin-proteasome system acts as the cell's quality control system by disposing of damaged, misshapen, and excess proteins. This system also regulates the level of proteins involved in several critical cell activities such as the timing of cell division and growth. In particular, cullin-7 is thought to help regulate proteins involved in the body's response to growth hormones, although its specific role in this process is unknown.

Health Conditions Related to Genetic Changes

3-M syndrome

At least 73 mutations in the CUL7 gene have been identified in people with 3-M syndrome, a disorder that causes skeletal anomalies including short stature (dwarfism) and unusual facial features. Most of these mutations substitute one protein building block (amino acid) for another amino acid in the cullin-7 protein or result in a cullin-7 protein that is abnormally short and nonfunctional.

Individuals in the Yakut population of the Russian province of Siberia with a variant of 3-M syndrome all have a particular mutation in both copies of the CUL7 gene in each cell. This mutation replaces the amino acid glutamine with a premature stop signal in the instructions for making the cullin-7 protein (written as Gln1553Ter or Q1553X), leading to production of an abnormally short protein.

Mutations in the CUL7 gene, including the Gln1553Ter mutation, prevent the cullin-7 protein from bringing together the components of the E3 ubiquitin ligase complex, interfering with the process of tagging unneeded proteins for degradation. The body's response to growth hormones may be impaired as a result. However, the specific relationship between CUL7 gene mutations and the signs and symptoms of 3-M syndrome are unknown.

Frequently Asked Questions

Short stature that is evident by early childhood, a distinctive facial appearance (such as a broad forehead, small mouth, and low-set ears), and skeletal abnormalities like bowed long bones or delayed bone age are typical. Parents often notice that their child does not grow as quickly as peers and may have a noticeably different facial profile.
definitive diagnosis requires genetic testing. A blood sample is sent for sequencing of the CUL7 gene to identify pathogenic variants. If a mutation is found, a repeat test on a second sample (e.g., a buccal swab) can confirm the result. In some cases, a broader panel for growth disorders may be used.
There is no cure that corrects the underlying genetic defect. Management focuses on growth and developmental support: growth hormone therapy may be considered if growth hormone deficiency is present, but its effectiveness varies. Regular monitoring for skeletal issues, feeding difficulties, and developmental delays is essential. Physical therapy, occupational therapy, and speech therapy can help address motor and speech delays.
CUL7 mutations are inherited in an autosomal recessive pattern, meaning both parents must carry one copy of the mutated gene for a child to be affected. Each child has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected. Genetic counseling and carrier testing for relatives can inform reproductive decisions.
Most individuals reach adulthood with a life expectancy similar to the general population, though they may experience short stature, mild to moderate developmental delays, and occasional orthopedic problems. Early intervention and regular medical follow‑up can help manage complications and improve quality of life.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss